Press release
Polycystic Kidney Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Otsuka Pharma, Sanofi S.A, Reata Pharma, Galapagos N.V, Janssen Pharma, Regulus Therapeutics
The Polycystic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Polycystic Kidney Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polycystic Kidney Disease Market.
Some of the key takeaways from the Polycystic Kidney Disease Pipeline Report: https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Polycystic Kidney Disease treatment therapies with a considerable amount of success over the years.
• Polycystic Kidney Disease companies working in the treatment market are Hannover Medical School, Otsuka Pharmaceutical, Rege Nephro Co., Ltd., Otsuka Pharmaceutical, and others, are developing therapies for the Polycystic Kidney Disease treatment
• Emerging Polycystic Kidney Disease therapies in the different phases of clinical trials are- Empagliflozin, Tolvaptan (OPC-41061), Tamibarotene, Tolvaptan Suspension, and others are expected to have a significant impact on the Polycystic Kidney Disease market in the coming years.
• In January 2025, Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company specializing in developing innovative medicines targeting microRNAs, has announced positive clinical and regulatory updates from its ADPKD program. The update includes encouraging topline results from an interim analysis of the fourth cohort in its Phase 1b Multiple Ascending Dose (MAD) study of farabursen (RGLS8429) for treating ADPKD. Additionally, the company provided insights into its recent successful End-of-Phase 1 meeting with the FDA.
• In April 2024, Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leading company in ribosomal RNA-targeted genetic therapies for rare diseases, has provided updates on its programs for ELX-02 and ZKN-013, including the Orphan Drug Designation (ODD) for ELX-02. The company has made significant progress in developing ELX-02 for treating Alport syndrome with nonsense mutations (NMAS). Furthermore, following its global licensing partnership with Almirall in March, Eloxx has initiated the development of ZKN-013 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Familial Adenomatous Polyposis (FAP) in patients with nonsense mutations. A recent publication on Autosomal Dominant Polycystic Kidney Disease (ADPKD) further highlights ELX-02's potential in addressing rare genetic kidney diseases caused by nonsense mutations.
• In January 2024, Regulus Therapeutics completed patient enrollment for the third cohort in its Phase Ib multiple-ascending dose (MAD) study of RGLS8429, a potential treatment for ADPKD. RGLS8429 aims to inhibit miR-17 and specifically target the kidneys. The Phase Ib MAD study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RGLS8429 in adults with ADPKD.
Polycystic Kidney Disease Overview
Polycystic Kidney Disease (PKD) is a genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. These cysts can enlarge the kidneys and interfere with their ability to function properly.
Get a Free Sample PDF Report to know more about Polycystic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Polycystic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
• Empagliflozin: Hannover Medical School
• Tolvaptan (OPC-41061): Otsuka Pharmaceutical
• Tamibarotene: Rege Nephro Co., Ltd.
• Tolvaptan Suspension: Otsuka Pharmaceutical
Polycystic Kidney Disease Route of Administration
Polycystic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Polycystic Kidney Disease Molecule Type
Polycystic Kidney Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Polycystic Kidney Disease Pipeline Therapeutics Assessment
• Polycystic Kidney Disease Assessment by Product Type
• Polycystic Kidney Disease By Stage and Product Type
• Polycystic Kidney Disease Assessment by Route of Administration
• Polycystic Kidney Disease By Stage and Route of Administration
• Polycystic Kidney Disease Assessment by Molecule Type
• Polycystic Kidney Disease by Stage and Molecule Type
DelveInsight's Polycystic Kidney Disease Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Polycystic Kidney Disease product details are provided in the report. Download the Polycystic Kidney Disease pipeline report to learn more about the emerging Polycystic Kidney Disease therapies
https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Polycystic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Polycystic Kidney Disease are - Otsuka Pharmaceutical, Sanofi S.A, Reata Pharmaceuticals, Galapagos N.V, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics, AceLink Therapeutics Inc., Pano Therapeutics, Inc., Exelixis, Inc., and others.
Polycystic Kidney Disease Pipeline Analysis:
The Polycystic Kidney Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Polycystic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycystic Kidney Disease Treatment.
• Polycystic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycystic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Polycystic Kidney Disease drugs and therapies
https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Polycystic Kidney Disease Pipeline Market Drivers
• Advancements in Genetic Research, Innovative Treatment Approaches, Increased Funding and Investments, Rising Prevalence, Enhanced Diagnostic Techniques, Patient Advocacy and Awareness, are some of the important factors that are fueling the Polycystic Kidney Disease Market.
Polycystic Kidney Disease Pipeline Market Barriers
• However, High Development Costs, Regulatory Challenges, Limited Treatment Options, Complex Disease Mechanism, Side Effects and Safety Concerns, Market Competitionand other factors are creating obstacles in the Polycystic Kidney Disease Market growth.
Scope of Polycystic Kidney Disease Pipeline Drug Insight
• Coverage: Global
• Key Polycystic Kidney Disease Companies: Hannover Medical School, Otsuka Pharmaceutical, Rege Nephro Co., Ltd., Otsuka Pharmaceutical, and others
• Key Polycystic Kidney Disease Therapies: Empagliflozin, Tolvaptan (OPC-41061), Tamibarotene, Tolvaptan Suspension, and others
• Polycystic Kidney Disease Therapeutic Assessment: Polycystic Kidney Disease current marketed and Polycystic Kidney Disease emerging therapies
• Polycystic Kidney Disease Market Dynamics: Polycystic Kidney Disease market drivers and Polycystic Kidney Disease market barriers
Request for Sample PDF Report for Polycystic Kidney Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Polycystic Kidney Disease Report Introduction
2. Polycystic Kidney Disease Executive Summary
3. Polycystic Kidney Disease Overview
4. Polycystic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5. Polycystic Kidney Disease Pipeline Therapeutics
6. Polycystic Kidney Disease Late Stage Products (Phase II/III)
7. Polycystic Kidney Disease Mid Stage Products (Phase II)
8. Polycystic Kidney Disease Early Stage Products (Phase I)
9. Polycystic Kidney Disease Preclinical Stage Products
10. Polycystic Kidney Disease Therapeutics Assessment
11. Polycystic Kidney Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Polycystic Kidney Disease Key Companies
14. Polycystic Kidney Disease Key Products
15. Polycystic Kidney Disease Unmet Needs
16 . Polycystic Kidney Disease Market Drivers and Barriers
17. Polycystic Kidney Disease Future Perspectives and Conclusion
18. Polycystic Kidney Disease Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Polycystic Kidney Disease Market https://www.delveinsight.com/report-store/polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Polycystic Kidney Disease Epidemiology https://www.delveinsight.com/report-store/polycystic-kidney-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Polycystic Kidney Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycystic Kidney Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Otsuka Pharma, Sanofi S.A, Reata Pharma, Galapagos N.V, Janssen Pharma, Regulus Therapeutics here
News-ID: 3888801 • Views: …
More Releases from DelveInsight Business Research
Tuberous Sclerosis Complex Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Ap …
(Albany, USA) DelveInsight's "Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Tuberous Sclerosis Complex, historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Tuberous Sclerosis Complex market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the…
Wilson's Disease Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, M …
(Albany, USA) DelveInsight's "Wilson's Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Wilson's Disease, historical and forecasted epidemiology as well as the Wilson's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Wilson's Disease market report also offers comprehensive insights into the Wilson's Disease market size, share, Wilson's Disease epidemiology, emerging therapies, market drivers and barriers,…
Fabry Disease Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medi …
(Albany, USA) DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Fabry Disease market report provides current treatment practices, emerging drugs, the market share of tmarkets. The Report also covers current Fabry Disease treatment practice/algorithm, market…
Eisenmenger Complex Drugs Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals …
(Albany, USA) DelveInsight's "Eisenmenger Complex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Eisenmenger Complex, historical and forecasted epidemiology as well as the Eisenmenger Complex market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Eisenmenger Complex market report provides current treatment practices, emerging drugs, the Eisenmenger Complex market share of individual therapies, and current and forecasted Eisenmenger…
More Releases for Disease
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,…
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
